GALT:US
$1.28
-
0.00%

Galectin Therapeutics Inc.
Insider Activity

Last updated: May 26, 2025, 12:06 AM ET

Profile

Company Description

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Sector

Healthcare

Industry

Biotechnology